Cargando…
驱动基因阳性非小细胞肺癌免疫治疗进展
Lung cancer is the most lethal malignancy around the world and non-small cell lung cancer (NSCLC) accounts for 80% of all cases. Most of the NSCLC patients has "driver gene mutations" and targeted therapy achieved a relatively good efficacy, but some patients progressed or relapsed after t...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976200/ https://www.ncbi.nlm.nih.gov/pubmed/35340163 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.06 |